Pharmaxis boost
October 7, 2010
AUSTRALIAN biotech company
Pharmaxis has confirmed plans to
boost US production, after being
granted marketing approval for its
Aridol asthma test by the Food and
Drug Administration (PD yest).
The company’s acting ceo, Gary
Phillips, told the Financial Review
that he expected US sales of Aridol
to commence early in 2011,
adding: “the warehouse racking out
our facility in Frenchs Forest is
being installed in the next couple of
weeks.”
Aridol is already allowed to be
sold in Australia, Europe and South
East Asia, with the current US
market of 150,000 tests per year
expected to climb because of
Aridol’s ease of use, Pharmaxis said.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Oct 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Oct 10